Suzetrigine - A Novel FDA-Approved Analgesic - Opportunities, Challenges and Future Perspectives: A Perspective Review
Abstract
BACKGROUND AND AIMS: Suzetrigine is the first class of non-opioid analgesics that selectively targets and blocks a key mediator in pain signal transmission, NaV1.8, which is expressed in the peripheral nociceptive neurons. Suzetrigine received approval from the U.S. Food and Drug Administration (FDA) on January 30, 2025. This review aims to explore Suzetrigine, a newly FDA-approved analgesic, by discussing its clinical opportunities, associated challenges, and future directions in pain management.
METHODS: We searched major databases (PubMed, Scopus, Web of Science, and ClinicalTrials.gov) and FDA sources for information on Suzetrigine and its role in pain management. The collected preclinical, clinical, and regulatory data were reviewed and analyzed to highlight their current evidence, challenges, and future potential.
RESULT AND DISCUSSION: Suzetrigine has been approved to treat acute pain after a sufficient and acceptable clinical trial. In terms of its usage in treating chronic pain, its effectiveness in cases of pregnant or lactating women and children, as well as whether it can be used in combination therapy, are still under observation. The brand name of Suzetrigine is JOURNAVX. So far, enough evidence has been provided to approve this drug only to treat acute pain for a short period of time. A lot of people with short-term pain are concerned about getting addicted to opioid analgesics when they are used as postoperative pain relievers. The invention of Suzetrigine…
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.